AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00477-06v1
50/11/3947    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wagenlehner, F. M. E.
Right arrow Articles by Naber, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagenlehner, F. M. E.
Right arrow Articles by Naber, K. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2006, p. 3947-3949, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00477-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose{triangledown}

Florian M. E. Wagenlehner,1* Martina Kinzig-Schippers,2 Uwe Tischmeyer,1 Christine Wagenlehner,1 Fritz Sörgel,2,3 and Kurt G. Naber1

Department of Urology, St. Elisabeth Hospital, Straubing,1 Institute for Biomedical and Pharmaceutical Research (IBMP), Nürnberg-Heroldsberg,2 Institute of Pharmacology, University of Essen, Essen, Germany3

Received 18 April 2006/ Returned for modification 7 July 2006/ Accepted 8 September 2006

Twelve volunteers received a single oral dose of 1,000 mg extended-release (XR) ciprofloxacin versus 500 mg levofloxacin to assess urinary bactericidal titers (UBTs) against common uropathogens. Areas under UBT-time curves were significantly larger for Proteus mirabilis with XR ciprofloxacin and for staphylococci with levofloxacin.

* Corresponding author. Mailing address: Department of Urology, Hospital St. Elisabeth, St. Elisabeth Str. 23, D-94315 Straubing, Germany. Phone: 49-9421-710-6702. Fax: 49-9421-710-1717. E-mail: Wagenlehner{at}AOL.com.

{triangledown} Published ahead of print on 18 September 2006.

Antimicrobial Agents and Chemotherapy, November 2006, p. 3947-3949, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00477-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.